摘要:
The present invention relates to mucin glycoconjugates, and to a process of producing mucin glycoconjugates. It relates to the biological, pharmaceutical and medical applications thereof. The invention notably provides mucin glycoconjugates which do not require a protein carrier, such as KHL, to induce an immune response (anti-Tn IgG).
摘要:
The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
摘要:
The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n(I) wherein M, T, B and n are as defined in claim 1.
摘要:
The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
摘要:
A genetically modified strain of M. tuberculosis or Mycobacterium bovis BCG is provided, wherein the genetically modified strain comprises at least one modified sequence comprising SEQ ID NO: 1, SEQ ID NO: 2, or both, having at least one mutation at T2, Q4, F8, A14, L28, L29, W43, G45, Y51, Q55, Q56, N66, M83, V90, M93, or F94 in SEQ ID NO:1; or at least one mutation at Q3, F7 A13, L27, W42, G44, Y50, Q54, N65, N67, M82, V89, M92, or F93 in SEQ ID NO:2, or a deletion at the terminal end of less than 20 amino acids. In a preferred embodiment, the mutation is at least one of T2H, Q4L, F8I, AI4R, L28A, L29S, W43R, G45T, Q55I, Q56A, N66I, N67A, M83I, V90R, M93T, or F94Q in SEQ ID NO:1, and Q3L, F7I, A13R, L27A, L28S, W42R, Q44T, Q54I, N65I, M82I, V89R, M92T, and F93Q in SEQ ID NO:2. Similarly, the genetically modified strain may also secrete ESAT-6 with a hexa-histidine tag, tetra-cysteine tag, or FLAG-tag, a GFP-fusion, or a short truncation at the C-terminal end of less than 20 amino acids.
摘要翻译:提供结核分枝杆菌或牛分枝杆菌BCG的遗传修饰菌株,其中所述遗传修饰菌株包含至少一个包含SEQ ID NO:1,SEQ ID NO:2或两者的经修饰的序列,或在T2处具有至少一个突变, SEQ ID NO:1中的Q4,F8,A14,L28,L29,W43,G45,Y51,Q55,Q56,N66,M83,V90,M93或F94; 或SEQ ID NO:2中的Q3,F7A13,L27,W42,G44,Y50,Q54,N65,N67,M82,V89,M92或F93的至少一个突变,或末端的缺失小于 20个氨基酸。 在优选实施方案中,突变是SEQ ID NO:1中的T2H,Q4L,F8I,AI4R,L28A,L29S,W43R,G45T,Q55I,Q56A,N66I,N67A,M83I,V90R,M93T或F94Q中的至少一种 ,以及SEQ ID NO:2中的Q3L,F7I,A13R,L27A,L28S,W42R,Q44T,Q54I,N65I,M82I,V89R,M92T和F93Q。 类似地,遗传修饰的菌株也可以分泌具有六组氨酸标签,四半胱氨酸标签或FLAG标签的ESAT-6,GFP-融合物或C末端的短截短小于20个氨基酸 。
摘要:
The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M bovis BCG::RDI or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer. These strains are also useful for the expression and presentation of heterologous antigens and molecule that are of therapeutic or prophylactic interest.
摘要:
An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
摘要:
The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
摘要:
A genetically modified strain of M. tuberculosis or Mycobacterium bovis BCG is provided, wherein the genetically modified strain comprises at least one modified sequence comprising SEQ ID NO: 1, SEQ ID NO: 2, or both, having at least one mutation at T2, Q4, F8, A14, L28, L29, W43, G45, Q55, Q56, N66, M83, V90, M93, or F94. In a preferred embodiment, the mutation is at least one of T2H, Q4L, F8I, A14R, L28A, L29S, W43R, G45T, Y51, Q55I, Q56A, N66I, N66A, M83I, V90R, M93T, or F94Q. Similarly, the genetically modified strain may also secrete ESAT-6 with a a histidine tag, tetra-cysteine tag or FLAG-tag, a GFP-fusion, or a short truncation at the C-terminal end of less than 20 amino acids.
摘要翻译:提供结核分枝杆菌或牛分枝杆菌BCG的遗传修饰菌株,其中所述遗传修饰菌株包含至少一个包含SEQ ID NO:1,SEQ ID NO:2或两者的经修饰的序列,或在T2处具有至少一个突变, Q4,F8,A14,L28,L29,W43,G45,Q55,Q56,N66,M83,V90,M93或F94。 在优选的实施方案中,突变是T2H,Q4L,F8I,A14R,L28A,L29S,W43R,G45T,Y51,Q55I,Q56A,N66I,N66A,M83I,V90R,M93T或F94Q中的至少一种。 类似地,遗传修饰的菌株也可以在小于20个氨基酸的C末端分泌具有组氨酸标签,四半胱氨酸标签或FLAG标签,GFP融合物或短截短的ESAT-6。
摘要:
The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSMα, PSMγ and PSMδ peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo. Thus, the PSMα, PSMγ and PSMδ peptides bound to these antigens may be used in the development of vaccines for preventing or treating infectious diseases or cancer